Corcept Q2 revenue $103.4M (up 13% YoY); EPS $0.24; reiterates FY22 revenue guidance

CORCEPT THERAPEUTICS INC

2022-Q2 EPS reported $0.44 revenue$197,074,000

Revenue $103.4M (Q2 2021: $91.6M); diluted EPS $0.24 vs $0.21.
Reiterated FY2022 revenue guidance of $400-$430 million.
Cash and investments $382.0 million, up $13.9 million from Q1 2022.
Initiated Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Expects Phase 2 AIWG (miricorilant) and NASH data in Q4 2022; NDA submission for relacorilant in Cushing's in H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.